8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

March 28, 2005

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-49616	88-0488686
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11588 Sorrento Valley Road, Suite 17, San Diego, California	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (858) 794-8889

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 8.01 Other Events.
	Item 9.01 Financial Statements and Exhibits.
SIGNATURES
EXHIBIT 99.1

Item 8.01 Other Events.

On March 28, 2005, Halozyme Therapeutics, Inc. announced that it filed a new drug application (“NDA”) with the U.S. Food and Drug Administration for Enhanze SC. The press release announcing the filing of the NDA is attached hereto as Exhibit 99.1 and is incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(c)   Exhibits.

Exhibit No.	Description
99.1	Press Release dated March 28, 2005.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Halozyme Therapeutics, Inc.
March 28, 2005	By:	/s/ David A. Ramsay
		David A. Ramsay
		Secretary and Chief Financial Officer

EX-99.1

                                                                    Exhibit 99.1

                                 (HALOZYME LOGO)


HALOZYME CONTACT                              INVESTOR RELATIONS CONTACTS
David A. Ramsay                               Ina McGuinness / Bruce Voss
Chief Financial Officer                       Lippert/Heilshorn & Associates
(858) 794-8889                                (310) 691-7100
dramsay@halozyme.com                          imcguinness@lhai.com

                                              MEDIA CONTACTS
                                              Kathy Sweeney / Joleen Schultz
                                              Mentus
                                              858-455-5500, x230/x215
                                              kwitz@mentus.com
                                              jschultz@mentus.com


                 HALOZYME THERAPEUTICS FILES NDA FOR ENHANZE SC

SAN DIEGO, MARCH 28, 2005 - Halozyme Therapeutics, Inc. (AMEX: HTI), a
development stage biopharmaceutical company developing and commercializing
recombinant human enzymes, today announced it has filed a New Drug Application
(NDA) for Enhanze SC(TM), the first product in Halozyme's Enhanze(TM)
Technology portfolio. Enhanze SC is a local formulation of recombinant human
hyaluronidase being developed as a "spreading agent" to enhance the drug
delivery of local anesthesia, contrast agents, and for subcutaneous fluid
replacement (also called hypodermoclysis). On March 3, 2005, Halozyme received
confirmation from the Food and Drug Administration (FDA) that Enhanze SC will be
designated a New Chemical Entity.

"We at Halozyme are proud to have met our stated goal of filing an NDA in the
first quarter of 2005 for Enhanze SC, an important product in our pipeline,"
said Jonathan Lim, MD, Halozyme's Chairman and CEO. "Filing a first NDA is a
major milestone for any company, but filing one merely 21 months after vector
construction, as Halozyme has achieved, is quite rare. It is a testament to the
efficiency of our development strategy and extraordinary efforts of our team."

Halozyme's hyaluronidase (rHuPH20) is a recombinant form of the naturally
occurring human enzyme and is being investigated for its ability to break down
hyaluronic acid (HA), the space-filling "gel"-like substance that is a major
component of tissues throughout the body. Hyaluronidase that is injected in the
skin or in the muscle can temporarily digest the HA gel to enhance the
penetration and diffusion of other injected drugs or fluids.

In August 2004, Halozyme signed an exclusive agreement with Baxter Healthcare
Corporation for Baxter to market, distribute, and sell Enhanze SC for certain
indications in the United States and Puerto Rico upon approval of the
therapeutic by the FDA. Upon approval, Baxter and Halozyme will be equal
partners in the commercialization of the product. In February 2005, Halozyme
signed a commercial manufacturing supply agreement with Avid Bioservices to
manufacture the recombinant human enzyme under current good manufacturing
practice (cGMP).

ABOUT HALOZYME THERAPEUTICS, INC.

Halozyme is a development stage biopharmaceutical company dedicated to
developing and commercializing recombinant human enzymes for the infertility,
ophthalmology, and oncology communities. The company's portfolio of products
under development is based on intellectual property covering the family of human
enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may
replace current animal slaughterhouse-derived enzymes that carry potential risks
of animal pathogen transmission and immunogenicity. The versatility of the first
enzyme, rHuPH20, enables Halozyme to develop the product as a medical device,
drug enhancement agent, and therapeutic biologic.

SAFE HARBOR STATEMENT

In addition to historical information, the statements set forth above include
forward-looking statements (including, without limitation, statements concerning
the Company's products under development, the timing of expected regulatory
filings, the regulatory approval of products under development and product
launch dates) that involve risk and uncertainties that could cause actual
results to differ materially from those in the forward-looking statements. The
forward-looking statements are also identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results could differ
materially from the expectations contained in forward-looking statements as a
result of several factors, including regulatory approval requirements and
competitive conditions. These and other factors that may result in differences
are discussed in greater detail in the company's reports on Forms 10-KSB, 10-QSB
and other filings with the Securities and Exchange Commission.

                                       ###